A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: An Eastern Cooperative Oncology Group study (E3296)

Jordan D. Berlin*, Sudeshna Adak, David J. Vaughn, David Flinker, Lawrence Blaszkowsky, Jules E. Harris, Al B Benson III

*Corresponding author for this work

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Gemcitabine has recently been compared favorably to 5-fluorouracil (5-FU) as the standard chemotherapy for advanced pancreas cancer. Based on phase I data that combining gemcitabine with 5-FU is safe and has evidence for clinical activity, a phase II trial was conducted by the Eastern Cooperative Oncology Group (ECOG). Patients with metastatic disease, good performance status and organ function were eligible and enrolled after providing informed consent. Patients were given gemcitabine (1000 mg/m2) followed by 5-FU (600 mg/m2) weekly for 3 weeks of every 4. Of 37 patients enrolled over a 3-month period, 36 were eligible. Partial responses were seen in 5 patients (14%), Median survival was 4.4 months with a 1-year survival rate of 8.6%, A randomized trial of the combination of 5-FU and gemcitabine versus gemcitabine alone is currently accruing patients in ECOG. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish (US)
Pages (from-to)215-218
Number of pages4
JournalOncology
Volume58
Issue number3
DOIs
StatePublished - Jan 1 2000

Fingerprint

gemcitabine
Pancreatic Neoplasms
Fluorouracil
Informed Consent
Survival Rate
Drug Therapy
Survival

Keywords

  • 5-Fluorouracil
  • Gemcitabine
  • Pancreas cancer
  • Phase II trial

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Berlin, Jordan D. ; Adak, Sudeshna ; Vaughn, David J. ; Flinker, David ; Blaszkowsky, Lawrence ; Harris, Jules E. ; Benson III, Al B. / A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer : An Eastern Cooperative Oncology Group study (E3296). In: Oncology. 2000 ; Vol. 58, No. 3. pp. 215-218.
@article{f0406a45bf76457c88ee00318d77b4f8,
title = "A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: An Eastern Cooperative Oncology Group study (E3296)",
abstract = "Gemcitabine has recently been compared favorably to 5-fluorouracil (5-FU) as the standard chemotherapy for advanced pancreas cancer. Based on phase I data that combining gemcitabine with 5-FU is safe and has evidence for clinical activity, a phase II trial was conducted by the Eastern Cooperative Oncology Group (ECOG). Patients with metastatic disease, good performance status and organ function were eligible and enrolled after providing informed consent. Patients were given gemcitabine (1000 mg/m2) followed by 5-FU (600 mg/m2) weekly for 3 weeks of every 4. Of 37 patients enrolled over a 3-month period, 36 were eligible. Partial responses were seen in 5 patients (14{\%}), Median survival was 4.4 months with a 1-year survival rate of 8.6{\%}, A randomized trial of the combination of 5-FU and gemcitabine versus gemcitabine alone is currently accruing patients in ECOG. Copyright (C) 2000 S. Karger AG, Basel.",
keywords = "5-Fluorouracil, Gemcitabine, Pancreas cancer, Phase II trial",
author = "Berlin, {Jordan D.} and Sudeshna Adak and Vaughn, {David J.} and David Flinker and Lawrence Blaszkowsky and Harris, {Jules E.} and {Benson III}, {Al B}",
year = "2000",
month = "1",
day = "1",
doi = "10.1159/000012103",
language = "English (US)",
volume = "58",
pages = "215--218",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "3",

}

A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer : An Eastern Cooperative Oncology Group study (E3296). / Berlin, Jordan D.; Adak, Sudeshna; Vaughn, David J.; Flinker, David; Blaszkowsky, Lawrence; Harris, Jules E.; Benson III, Al B.

In: Oncology, Vol. 58, No. 3, 01.01.2000, p. 215-218.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer

T2 - An Eastern Cooperative Oncology Group study (E3296)

AU - Berlin, Jordan D.

AU - Adak, Sudeshna

AU - Vaughn, David J.

AU - Flinker, David

AU - Blaszkowsky, Lawrence

AU - Harris, Jules E.

AU - Benson III, Al B

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Gemcitabine has recently been compared favorably to 5-fluorouracil (5-FU) as the standard chemotherapy for advanced pancreas cancer. Based on phase I data that combining gemcitabine with 5-FU is safe and has evidence for clinical activity, a phase II trial was conducted by the Eastern Cooperative Oncology Group (ECOG). Patients with metastatic disease, good performance status and organ function were eligible and enrolled after providing informed consent. Patients were given gemcitabine (1000 mg/m2) followed by 5-FU (600 mg/m2) weekly for 3 weeks of every 4. Of 37 patients enrolled over a 3-month period, 36 were eligible. Partial responses were seen in 5 patients (14%), Median survival was 4.4 months with a 1-year survival rate of 8.6%, A randomized trial of the combination of 5-FU and gemcitabine versus gemcitabine alone is currently accruing patients in ECOG. Copyright (C) 2000 S. Karger AG, Basel.

AB - Gemcitabine has recently been compared favorably to 5-fluorouracil (5-FU) as the standard chemotherapy for advanced pancreas cancer. Based on phase I data that combining gemcitabine with 5-FU is safe and has evidence for clinical activity, a phase II trial was conducted by the Eastern Cooperative Oncology Group (ECOG). Patients with metastatic disease, good performance status and organ function were eligible and enrolled after providing informed consent. Patients were given gemcitabine (1000 mg/m2) followed by 5-FU (600 mg/m2) weekly for 3 weeks of every 4. Of 37 patients enrolled over a 3-month period, 36 were eligible. Partial responses were seen in 5 patients (14%), Median survival was 4.4 months with a 1-year survival rate of 8.6%, A randomized trial of the combination of 5-FU and gemcitabine versus gemcitabine alone is currently accruing patients in ECOG. Copyright (C) 2000 S. Karger AG, Basel.

KW - 5-Fluorouracil

KW - Gemcitabine

KW - Pancreas cancer

KW - Phase II trial

UR - http://www.scopus.com/inward/record.url?scp=0034029777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034029777&partnerID=8YFLogxK

U2 - 10.1159/000012103

DO - 10.1159/000012103

M3 - Article

C2 - 10765123

AN - SCOPUS:0034029777

VL - 58

SP - 215

EP - 218

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 3

ER -